Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Assets Average (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Assets Average for 15 consecutive years, with $825.8 million as the latest value for Q1 2026.

  • For Q1 2026, Assets Average fell 2.1% year-over-year to $825.8 million; the TTM value through Mar 2026 reached $825.8 million, down 2.1%, while the annual FY2025 figure was $838.6 million, 14.71% up from the prior year.
  • Assets Average hit $825.8 million in Q1 2026 for Corcept Therapeutics, down from $830.1 million in the prior quarter.
  • Across five years, Assets Average topped out at $843.5 million in Q1 2025 and bottomed at $445.9 million in Q1 2022.
  • Average Assets Average over 5 years is $668.4 million, with a median of $638.7 million recorded in 2024.
  • Year-over-year, Assets Average dropped 20.66% in 2022 and then surged 34.69% in 2023.
  • Corcept Therapeutics' Assets Average stood at $558.3 million in 2022, then grew by 8.85% to $607.8 million in 2023, then skyrocketed by 33.67% to $812.4 million in 2024, then rose by 2.18% to $830.1 million in 2025, then dropped by 0.53% to $825.8 million in 2026.
  • According to Business Quant data, Assets Average over the past three periods came in at $825.8 million, $830.1 million, and $812.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.